SPRB Stock Forecast & Price Target

Spruce Biosciences is positioned favorably because TA-ERT addresses MPS IIIB, a rare disease with significant unmet need, and the company’s development strategy is aligned with a regulatory environment that increasingly supports accelerated approval pathways for lysosomal storage disorders when clinical benefit is supported by concordant biomarker and patient outcome data. The cited evidence suggests the company has a credible path to approval through reductions in CSF heparan sulfate non-reducing ends alongside stabilization in cognition, communication, gross and fine motor function, and cortical gray matter volume, while the upcoming TrAnsform confirmatory study and planned EAP could further strengthen the totality of evidence and broaden early patient access. Financially and strategically, the stock appears compelling at a roughly $130M market cap against modeled peak sales of about $170M and a PRV value of $150-200M, with shares down 47% YTD despite $96M in cash providing runway into 2H27 and the lead program’s BLA submission on track for 4Q26.

Spruce Biosciences is facing a fundamentally challenging risk-reward profile because TA-ERT remains a very small, capital-intensive development program with only ~14 patients planned for the global randomized TrAnsform confirmatory study over roughly 260 weeks, leaving limited statistical power and substantial dependence on biomarker and natural-history comparisons rather than large, definitive clinical evidence. Although the company ended the quarter with $96M in cash and runway into 2H27, that balance must support ongoing clinical, CMC, and launch preparation efforts ahead of the planned 4Q26 study and EAP start, while the $5.5M strategic investment is modest relative to the execution burden of a rare-disease biologic program. Even with a potentially favorable FDA backdrop and a theoretical peak sales opportunity above $300M, the case is still weakened by manufacturing complexity, execution risk, and the binary uncertainty around whether TA-ERT will ultimately convert a niche unmet-need story into a commercially durable approved therapy.